Working... Menu

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01670071
Recruitment Status : Terminated (The study was terminated due to insufficient sample size and protocol compliance issue.)
First Posted : August 21, 2012
Last Update Posted : April 13, 2016
Information provided by (Responsible Party):
Johnson & Johnson Taiwan Ltd

Brief Summary:
The purpose of this study is to compare the effect of oral paliperidone extended-release and oral risperidone immediate-release on cognitive function, especially the category fluency of Cognitive Abilities Screening Instrument, Chinese version (CASI C-2.0), in patients with an established diagnosis of schizophrenia.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: Paliperidone extended-release Drug: Risperidone immediate-release Phase 4

Detailed Description:
This is a 28-week, randomized (the study medication is assigned by chance), open-label (all people know the identity of the intervention), active-controlled (patients are assigned to either a recognized effective treatment or the study medication) comparative study. All patients will enter a run-in period to receive a stable therapeutic dose of oral risperidone immediate-release for at least 4 weeks. After the 4-week run-in period, patients will be randomly assigned to either remain on oral risperidone immediate-release (IR) or to receive a therapeutic dose of oral paliperidone extended-release (ER) and patients will be prospectively followed for a 24-week treatment phase. The treatment phase is composed of a 4-week flexible dose period followed by a 20-week stable dose period. During the 4-week flexible dose period, the dose of paliperidone ER or risperidone IR may be increased or decreased for each patient if clinically indicated (eg, significant side effects emerge or there is evidence of a lack of efficacy). At the end of 4-week flexible dose period, the final dose should be maintained for the 20-week fixed-dose period. Efficacy and safety will be assessed at baseline (Week 0) and Weeks 4, 12, and 24.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia
Study Start Date : January 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: Paliperidone extended-release Drug: Paliperidone extended-release
Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
Other Name: Paliperidone

Active Comparator: Risperidone immediate-release Drug: Risperidone immediate-release
Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
Other Name: Risperidone IR

Primary Outcome Measures :
  1. Change in category fluency score of cognitive function scale (Cognitive Abilities Screening Instrument, Chinese version [CASI C-2.0]) from baseline to Week 24 [ Time Frame: Baseline (Week 0), Week 4, Week 12 and Week 24 ]
    CASI C-2.0 will be used to measure patient's cognitive ability. The range of CASI score is 0 to 100 (a higher score indicating better performance and is influenced by patient's educational level). The CASI C-2.0 provides quantitative assessment on 9 cognitive domains and 20 questions, including attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, category fluency, abstraction, and judgment.

Secondary Outcome Measures :
  1. Change from baseline to Week 24 in score of Modified Wisconsin Card Sorting Test (MWCST) short version [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ]
    The WCST was developed to assess abstract reasoning and ability to shift cognitive strategies in response to environmental changes. The materials consist of a pack of 4 stimulus cards and 48 response cards which are devised so that each card contains from 1 to 4 identical figures of a single color. Individually administered, it requires the patient to sort the cards according to different principles (ie, by color, form, or number). As the test progresses, there are unannounced shifts in the sorting principle which require the patient to alter his or her approach.

  2. Change from baseline in score of Continuous Performance Test (CPT) [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ]
    CPT is an attention test. Response patterns on the CPT II is used as an aid in monitoring treatment effectiveness. For example, some response patterns suggest inattentiveness or impulsivity, while other response patterns may indicate activation/arousal problems or difficulties maintaining vigilance.

  3. Change from baseline in score of Personal and Social Performance (PSP) scale [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ]
    The PSP is a clinician-rated instrument providing an overall rating of personal and social functioning in subjects with schizophrenia on a scale of 1-100. Four domains of functioning are considered in the rating: 1) socially useful activities, including work and study, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior.

  4. Change from baseline in score of Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ]
    The PANSS is a medical scale used for measuring symptom severity of patients with schizophrenia. The neuropsychiatric symptoms of schizophrenia will be assessed using the 30-item PANSS scale, which provides a total score (sum of the scores of all 30 items). Each scale is rated 1 (absent) to 7 (extreme).

  5. Change from baseline in score of Clinical Global Impression-severity (CGI-S) scale [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ]
    The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). This scale permits a global evaluation of the patient's condition at a given time.

  6. Change from baseline in score of Medication Satisfaction Questionnaire (MSQ) [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ]
    MSQ is designed to assess treatment satisfaction among patients with schizophrenia. It consists of 1 question: "Overall, how satisfied are you with your current antipsychotic medication(s)?" with responses assessed on a 7-point scale rated as follows: 1=extremely dissatisfied, 2=very dissatisfied, 3=somewhat dissatisfied, 4=neither satisfied nor dissatisfied, 5=somewhat satisfied, 6=very satisfied, and 7=extremely satisfied.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with schizophrenia
  • Cognitive abilities screening instrument C-2.0 total score between 50 and 85 (inclusive) at baseline
  • Baseline positive and negative syndrome scale score between 60 and 85 (inclusive)
  • Clinical global impression-severity change less than or equal to 1 in the month prior to randomization
  • Patients on a stable therapeutic dose of oral risperidone IR (between 3-6 mg/day) for at least 4 weeks prior to randomization

Exclusion Criteria:

  • Treatment refractory patients, defined as failure of more than or equal to 2 adequate trials of second generation antipsychotic treatment for schizophrenia
  • History of neuroleptic malignant syndrome
  • Allergy or hypersensitivity to risperidone or paliperidone, or to any of the excipients of oral risperidone IR or paliperidone ER tablets
  • Participants who have taken paliperidone ER in the past
  • Participants who have been treated with clozapine or any long-acting injectable (depot) antipsychotic within 3 months before randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01670071

Layout table for location information
Bali Township, Taipei County, Taiwan
Hua Lian, Taiwan
Kaohsiung, Taiwan
Sponsors and Collaborators
Johnson & Johnson Taiwan Ltd
Layout table for investigator information
Study Director: Johnson & Johnson Taiwan Ltd Clinical Trial Johnson & Johnson Taiwan Ltd

Additional Information:
Layout table for additonal information
Responsible Party: Johnson & Johnson Taiwan Ltd Identifier: NCT01670071     History of Changes
Other Study ID Numbers: CR100817
R076477SCH4066 ( Other Identifier: Johnson & Johnson Taiwan Ltd )
First Posted: August 21, 2012    Key Record Dates
Last Update Posted: April 13, 2016
Last Verified: April 2016

Keywords provided by Johnson & Johnson Taiwan Ltd:
Paliperidone extended-release (ER)
Risperidone immediate-release (IR)

Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Paliperidone Palmitate
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Serotonin 5-HT2 Receptor Antagonists
Dopamine D2 Receptor Antagonists